Daniela Bianconi

机构：MSD (Austria) · ORCID：0000-0002-8102-4199

发表论文 28 篇 · 总被引 447 次 · h-index 11

代表论文

Integrins in the Spotlight of Cancer (2016 · International Journal of Molecular Sciences · 被引 158)
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid (2019 · Therapeutic Advances in Medical Oncology · 被引 48)
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients (2020 · Journal of Clinical Medicine · 被引 35)
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC (2020 · Therapeutic Advances in Medical Oncology · 被引 23)
Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy (2018 · Medical Oncology · 被引 22)
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients (2015 · Thrombosis Research · 被引 22)